Hair-Regrowth Drugs in 2026: PP405, Clascoterone and the Real Evidence

Hair-loss headlines often move from a laboratory mechanism to “cure” in one sentence. Two current programmes deserve attention without that shortcut. PP405 aims to reactivate dormant hair-follicle stem cells. A 5% clascoterone scalp solution aims to block androgen signalling locally.

Both have human trial programmes. Neither was an approved hair-regrowth medicine when RoboFutur checked the evidence on 18 July 2026.

PP405: an early regenerative signal

PP405 inhibits the mitochondrial pyruvate carrier, a metabolic switch researchers believe can help move dormant follicle stem cells back into an active state. The registered phase 2a study, NCT06393452, enrolled 78 adults with androgenetic alopecia in a randomised, vehicle-controlled design. Its primary focus was safety and local tolerability, with pharmacokinetics and exploratory efficacy measures.

Pelage reported that the treatment was well tolerated and that no systemic absorption was detected in blood. In a selected group of men with more advanced hair loss, the company said 31% of PP405 recipients achieved more than a 20% increase in hair density at week eight, compared with 0% on vehicle.

That result is promising and limited. It is a sponsor-reported exploratory subgroup after a small study, not a complete peer-reviewed efficacy dataset. The registry did not display posted results when checked. A larger late-stage trial must show the size, durability and consistency of the effect across women, men, hair types and degrees of loss.

Clascoterone: local androgen blockade

Androgenetic alopecia is driven partly by follicle sensitivity to androgens. Clascoterone is an androgen-receptor inhibitor designed for topical use. A 1% cream is FDA-approved for acne, but that does not approve the separate 5% scalp solution for hair loss.

SCALP1, NCT05910450, and its companion phase 3 programme compare the 5% solution with vehicle in men with pattern hair loss. The trials measure non-vellus hair count and participant assessments over six months, with an extension examining longer use.

Cosmo describes the hair-loss formulation as investigational. Sponsor announcements of positive topline results are useful signals, but regulatory review requires full efficacy, safety, manufacturing and labelling data. Reusing an acne medicine on the scalp without approval is not equivalent to the tested product or protocol.

Why percentage headlines can mislead

A relative improvement versus placebo can sound enormous when the absolute change is modest. Hair studies also vary in the measured scalp area, baseline density, lighting, grooming and definition of a responder. The most informative report gives absolute hair counts, confidence intervals, every prespecified endpoint, discontinuations and standardised photographs.

Time matters. Hair cycles are slow. An eight-week signal can justify a larger study, but long-term evidence must show whether new hairs mature, remain present and produce a visible benefit meaningful to participants.

Existing treatments set the comparison

New candidates do not compete with nothing. Minoxidil and finasteride have established indications for particular patients, with known limitations and risks. A new treatment should demonstrate either better benefit, better tolerability, usefulness for a broader population or a complementary mechanism.

Because hair loss has multiple causes, a drug tested for androgenetic alopecia should not be assumed to treat autoimmune alopecia, scarring, nutritional deficiency or medication-related shedding. Diagnosis changes the treatment question.

What to watch next

For PP405, watch for a registered late-stage protocol, complete participant-level accounting and independently scrutinised results. For clascoterone, watch regulatory submissions and the final labels authorities actually approve. For both, follow adverse effects, systemic exposure, durability and outcomes in women as carefully as the most flattering responder images.

Avoid online products claiming to contain an investigational compound. Their identity, concentration and manufacturing quality are not guaranteed, and a trial formulation is not a self-treatment instruction.

The verdict

PP405 and clascoterone represent two credible but different ideas: reactivate follicle stem cells or reduce local androgen signalling. Human studies make them more than laboratory speculation.

The honest 2026 status is still investigational for hair loss. Positive sponsor releases should lead to better trials and regulatory review—not to a claim that baldness has already been cured.